POLYTECH HEALTH & AESTHETICS GMBH
KEY FACTS AT A GLANCE
POLYTECH HEALTH & AESTHETICS GMBH
REVENUES in €mn
As of 30 June 2017
We intend to support Polytech in consistently focusing on the medical-technical advancement of its implants as well as on its excellent ‘made in Germany’ manufacturing quality. We are very pleased to have settled the succession issue in this family business by way of a management buyout. This is again proof of our outstanding position in Germany’s Mittelstand.
PROVIDER OF HIGH-QUALITY SILICONE IMPLANTS
Polytech is a leading player in the development and production of silicone implants in Europe and the sole German manufacturer of such products. The company specialises in breast implants used in reconstructive surgery after illness and in aesthetic plastic surgery.
The company has grown strongly in recent years. This expansion is based on production (under clean-room conditions) in Germany, which conforms to highest quality standards, and the company’s innovative capacity. Polytech has developed surface textures for its products that lead to a clear reduction in the rate of complications.
POTENTIAL FOR DEVELOPMENT
In view of the very positive response to implants “made in Germany”, Polytech has considerably expanded its distribution activities. So far, the company generates around half of its revenues in Germany and other Western European countries. However, it increasingly sells its medical technology products worldwide, currently in over 70 countries. Polytech serves a growth market that is expected to develop worldwide by an annual rate of some six percent in the next few years. Growth is driven among others by rising prosperity and demographic change in industrialised countries. Polytech was previously family-run and is now at a new stage in its development.
2016 FINANCIAL YEAR
The company has kept its course with sustained dynamic growth. Total output and earnings are expected to be well above the previous year’s figures.
OUTLOOK AND OBJECTIVES
DBAG and DBAG Fund VI acquired a majority stake in the business in the fourth quarter of 2016. The focus in 2017 will first be on initiating the measures agreed on with management at the beginning of the investment. These include significantly increasing the company’s capacities for clean-room production, which is expected to be completed in the first quarter of 2017, and further strengthen the sales organisation. The company expects demand to remain at a high level and has therefore budgeted an increase in revenues and earnings, based on the higher production capacities.
Tom Alzin joined Deutsche Beteiligungs AG in 2004 and became a Managing Director in 2011.
He studied Business Administration at HEC Lausanne and at the London School of Economics.
Tom Alzin has more than twelve years of experience in private equity. During that time, he gained a wealth of knowledge, particularly in the mechanical and plant engineering and in the services sector. Tom Alzin was involved in numerous acquisitions and realisations and also in the IPO of Homag. The realisations of Homag and Spheros, subsequent to their very successful development, are two of his most successful transactions. Tom Alzin also led the investment process in FDG, Pfaudler, Schülerhilfe, Telio, Polytech and duagon and sits on the advisory councils of the companies, which are still part of the DBAG portfolio.